Photographer: Krisztian Bocsi/Bloomberg

Germany’s Stada Urged by Investor to Replace Five Directors

Updated on
  • Active Ownership also proposes ending transfer limits on stock
  • Proposals submitted for annual shareholder meeting on June 9

Stada Arzneimittel AG, Germany’s largest maker of generic drugs, was urged by one of its top shareholders to replace five board members and remove a restriction on transfer of shares.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.